BQURA's R&D News Curation
View more R&D news
R&D
Partnering Opportunity for ABN401 (Vabametkib): A Potent Oral MET Inhibitor Targeting Global Markets
R&D
D&D Pharmatech Highlights GLP-1 Agonists’ Potential for Parkinson’s Treatment Amid Growing Research Evidence
R&D
Alteogen Signs Exclusive Licensing Deal with AstraZeneca’s MedImmune for ALT-B4 SC Cancer Therapy
R&D
Onconic Therapeutics’ Cancer Drug ‘Nesuparib’ Receives FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer
R&D
AprilBio’s IL-18 Inhibitor ‘APB-R3’ Begins Phase 2 Trial in the U.S.
R&D
Excell Therapeutics Completes FDA DMF Registration for MSC Culture Medium ‘CellCor MSC CD AOF’
R&D
Abclon to Pursue Fast-Track Approval for CAR-T Therapy ‘AT101’ Following Positive Phase 2 Progress
R&D
BridgeBio Therapeutics Advances Phase 1 Trial of 4th-Generation EGFR Inhibitor ‘BBT-207’
R&D
Genome & Company Licenses Immuno-Oncology Drug ‘GENA-104’ to UK’s Ellipses Pharma
R&D
DAAN Biotherapeutics Licenses Novel Anticancer Antibody to LigaChem Biosciences for ADC Development